NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $32.75 -2.26 (-6.46%) Closing price 04:00 PM EasternExtended Trading$33.61 +0.86 (+2.63%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Agios Pharmaceuticals Stock (NASDAQ:AGIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Agios Pharmaceuticals alerts:Sign Up Key Stats Today's Range$29.15▼$33.5050-Day Range$26.51▼$44.0152-Week Range$22.24▼$46.00Volume3.13 million shsAverage Volume1.02 million shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$40.38Consensus RatingHold Company Overview Agios Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction. Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations. Tibsovo (ivosidenib) is approved for treating relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and for certain advanced cholangiocarcinoma patients. Idhifa (enasidenib) addresses AML patients bearing an IDH2 mutation. These targeted therapies represent some of the first metabolism-based oncology treatments on the market. Beyond its approved products, Agios maintains a diverse pipeline in both oncology and rare genetic diseases. The company is developing mitapivat, a pyruvate kinase activator for chronic hemolytic anemias, in collaboration with Servier for ex-U.S. commercialization. Additional research programs leverage Agios’s expertise in metabolic targets to pursue next-generation candidates for hematologic malignancies and solid tumors. Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions. Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge. Leadership is currently headed by President and CEO Jackie Fouse, with Catherine Shacklett serving as Chief Financial Officer. The company continues to expand its scientific capabilities and strategic collaborations as it advances its mission of translating metabolism research into life-changing treatments.AI Generated. May Contain Errors. Read More Agios Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreAGIO MarketRank™: Agios Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 688th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingAgios Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialAgios Pharmaceuticals has a consensus price target of $40.38, representing about 23.3% upside from its current price of $32.75.Amount of Analyst CoverageAgios Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Agios Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.33) to ($4.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.78% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 6.42.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 1.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.55 News SentimentAgios Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Agios Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 4 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.40% of the stock of Agios Pharmaceuticals is held by insiders.Percentage Held by InstitutionsAgios Pharmaceuticals has minimal institutional ownership at this time.Read more about Agios Pharmaceuticals' insider trading history. Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGIO Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOJuly 30 at 10:00 AM | prnewswire.comAgios Reports Second Quarter 2026 Financial Results and Provides Business UpdateJuly 30 at 6:30 AM | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 30 at 1:00 AM | Porter & Company (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOJuly 28 at 5:24 PM | globenewswire.comHC Wainwright Has Pessimistic View of AGIO FY2026 EarningsJuly 25, 2026 | americanbankingnews.comWhy Is AGIO Stock Falling Today?July 22, 2026 | finance.yahoo.comAgios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)July 21, 2026 | msn.comAgios scraps sickle cell drug programme on underwhelming Phase II dataJuly 21, 2026 | msn.comSee More Headlines AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $27.22 at the beginning of the year. Since then, AGIO stock has increased by 20.3% and is now trading at $32.75. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.65) by $0.04. The biopharmaceutical company had revenue of $44.75 million for the quarter, compared to analysts' expectations of $26.40 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative trailing twelve-month return on equity of 34.11%. Read the conference call transcript. When did Agios Pharmaceuticals IPO? Agios Pharmaceuticals (AGIO) raised $88 million in an initial public offering on Wednesday, July 24th 2013. The company issued 5,888,888 shares at $14.00-$16.00 per share. Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.17%), Hennion & Walsh Asset Management Inc. (0.06%), Handelsbanken Fonder AB (0.04%) and Versant Capital Management Inc. Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Sarah Gheuens, Cecilia Jones, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek, Krishnan Viswanadhan and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Today7/30/2026Last Earnings7/30/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AGIO's financial health is in the Green zone, according to TradeSmith. AGIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGIO CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year Founded2008Price Target and Rating Average Price Target for Agios Pharmaceuticals$40.38 High Price Target$55.00 Low Price Target$31.00 Potential Upside/Downside+23.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($7.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.78 million Net Margins-639.84% Pretax Margin-641.38% Return on Equity-34.11% Return on Assets-31.66% Debt Debt-to-Equity RatioN/A Current Ratio14.19 Quick Ratio13.59 Sales & Book Value Annual Sales$54.03 million Price / Sales36.05 Cash FlowN/A Price / Cash FlowN/A Book Value$20.46 per share Price / Book1.60Miscellaneous Outstanding Shares59,470,000Free Float56,261,000Market Cap$1.95 billion OptionableOptionable Beta0.54 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AGIO) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredBREAKING: Bill Gates Says It’s “Worth 10 Microsofts”Nvidia is up 203% this year. Microsoft, Amazon, Apple, and Alphabet have each surged between 36% and 62%. But ...Traders Agency | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy Biggest Setup in 31 Years Started in RiyadhOn June 9, 2024, a 50-year pact between Washington and Riyadh quietly expired, cracking one of the hidden pill...Golden Portfolio | SponsoredSell SpaceX Now. Buy This Instead.Rob Spivey traveled to SpaceX's Starbase, Texas headquarters to uncover what Wall Street missed in the company...Altimetry | SponsoredEveryone is buzzing about the "Presidio Initiative"A billionaire wrote a single 20 million dollar check at a former U.S. military base near the Golden Gate Bridg...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
